BCM leading COVID-19 vaccine study in pregnant women

Baylor College of Medicine has been selected as the lead site in a study to determine what immune responses women have to various COVID-19 vaccines when administered during or just after pregnancy.

The study will evaluate the safety of and immune responses created by various COVID-19 vaccines currently approved under Emergency Use Authorization by the FDA. The study also will assess how vaccine-induced antibodies transfer to infants both through the placenta and breast milk, and how they could provide protection against COVID-19 in the first year of the infant’s life.

“We know that with other vaccines given during pregnancy, such as the flu and pertussis vaccines, mothers are able to pass along protection to their baby. We still have much to learn regarding infant protection through maternal immunization with COVID-19 vaccines,” said Dr. Flor Munoz, associate professor of pediatric infectious diseases at Baylor and principal investigator of the study’s lead site at Baylor.

This is a national, multicenter study. Texas Children’s Hospital and Texas Children’s Pavilion for Women are participating in the local study.

Vaccines will not be provided through this study. The study will enroll pregnant mothers who have received or will receive an authorized SARS-CoV-2 vaccine during pregnancy. The mothers and their infants will be followed for up to 12 months after delivery. Mothers who recently delivered and have received an authorized SARS-CoV-2 vaccine within the first 2 months after delivery, and their babies, also can enroll in the study.

Individuals who are interested in joining the trial can call 409-420-6513, register here or scan the QR code below to find the application to join the trial.

The study is being conducted by the Infectious Disease Clinical Research Consortium in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Find more information on the national study here.